CGEM Q4 2023 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

Q4 2023 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

-$77,000

Operating Income

-$45M

Net Income

-$24M

EPS (Diluted)

$-0.56

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$484M

Total Liabilities

$30M

Stockholders' Equity

$454M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$77,000	$0	—
Operating Income	-$45M	-$33M	-39.5%
Net Income	-$24M	-$27M	+11.1%